Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06596694
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-09-11
Brief Title:
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers MK-1022-011
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 12 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Researchers want to learn if patritumab deruxtecan MK-1022 can treat certain gastrointestinal GI cancers The GI cancers being studied are advanced the cancer has spread to other parts of the body The goals of this study are to learn
About the safety and how well people tolerate of patritumab deruxtecan
How many people have the cancer respond get smaller or go away to treatment
About the safety and how well people tolerate of patritumab deruxtecan
How many people have the cancer respond get smaller or go away to treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None